Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
5 we » _ we (Expand Search), 5 wt (Expand Search), 5 w (Expand Search)
-
101
-
102
-
103
PPM1A facilitates both nuclear distribution and transcription potency of YAP/TAZ.
Published 2021“…<b>(B–D)</b> Transcription potency of YAP (5 ng), which was suppressed by coexpression of MST1 (50 ng) (B), LATS1 (500 ng) (C), or MAP4K1 (50 ng) (D), was markedly recovered by cotransfection of wild-type PPM1A but not the enzyme-dead PPM1A (D239N). …”
-
104
-
105
-
106
Table_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.docx
Published 2022“…However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
-
107
-
108
-
109
-
110
Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD)
Published 2020“…Bronchoalveolar lavage (BAL) fluid was obtained from 12 former smokers with COPD and 5 non-smoking, non-asthmatic healthy control volunteers. …”
-
111
-
112
Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif
Published 2025“…Moreover, 5 of the decreased autoantibodies can also be applied for supervising bone metastasis in lung adenocarcinoma. …”
-
113
-
114
Time course of the variances (<i>V</i><sub><i>ip</i></sub>, <i>V</i><sub><i>g</i></sub>) after switching interaction strength.
Published 2021“…The two variances of the non-target output genes decrease, while <i>V</i><sub><i>g</i></sub> < <i>V</i><sub><i>ip</i></sub> is maintained throughout the evolutionary course (a). …”
-
115
Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF
Published 2024“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
-
116
DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf
Published 2022“…However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
-
117
-
118
-
119
-
120